Next Article in Journal
Mechanistic of Vesicular Ethosomes and Elastic Liposomes on Permeation Profiles of Acyclovir across Artificial Membrane, Human Cultured EpiDerm, and Rat Skin: In Vitro-Ex Vivo Study
Previous Article in Journal
Healing Effect of a Nano-Functionalized Medical-Grade Honey for the Treatment of Infected Wounds
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 9
10.3390/pharmaceutics15092188
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceutics 2019, 11(1), 15.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15

by
Li-qian Ci
1,2,†,
Zhi-gang Huang
1,†,
Feng-mei Lv
2,
Jun Wang
2,
Ling-lin Feng
3,
Feng Sun
4,
Shui-juan Cao
5,
Zhe-peng Liu
2,
Yu Liu
1,*,
Gang Wei
1 and
Wei-yue Lu
1
1
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai 201203, China
2
School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China
3
NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Room 904, No 1 Research Building, 2140 Xietu Road, Shanghai 200032, China
4
Chinese Academy of Sciences Shanghai Institute of Materia Medica, Shanghai 201203, China
5
Experimental Teaching Center, School of Pharmacy, Fudan University, Shanghai 201203, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2023, 15(9), 2188; https://doi.org/10.3390/pharmaceutics15092188
Submission received: 2 February 2023 / Accepted: 17 August 2023 / Published: 24 August 2023
Browse Figures
Versions Notes

1. Error in Figure

In the original publication [1], there was a mistake in Figure 3A as published. When conducting fluorescent photographing, more than one pictures were taken at the beginning for adjust the fluorescent setting parameters using the cells incubated with free probes. During the preparation of the figure, all the figures were put in one file for convenience of batch processing and a photograph from cells incubated with free probes was mistakenly used as the NC-120 min. The corrected Figure 3 appears below.
In the original publication [1], there was also a mistake in Figure 6G as published. When preparing microscopy sections, more than one section was obtained from every animal. A mislabel of another section from the same mice treated with free drug/FG as NC/FG. The corrected Figure 6G appears below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Ci, L.-q.; Huang, Z.-g.; Lv, F.-m.; Wang, J.; Feng, L.-l.; Sun, F.; Cao, S.-j.; Liu, Z.-p.; Liu, Y.; Wei, G.; et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15. [Google Scholar] [CrossRef] [PubMed]
Pharmaceutics 15 02188 g003
Figure 3. Cellular uptake and cytotoxicity in cervical cancer-related cell lines. (A) Representative CLSM images of TC-1 cells co-incubated with 6-coumarin (C6)-labeled NC@PDA-NH2, NC, or free probe C6 (green signal). The nucleus was stained with 2-(4-amidinophenyl)-6-indolecarbamindine dihydrochloride (DAPI; blue) and the lysosomes were stained with LysoTracker Red. (B) Flow cytometry analysis on the fluorescent intensity of cells after co-incubation for 2 h with C6-labeled NC@PDA-NH2, NC, or free probe in TC-1 cells. (C) Intracellular drug content after co-incubation for 72 h with NC@PDA-NH2, NC, or free imatinib in TC-1 cells (n = 5, mean ± SD, ** represents p < 0.01). (D,E) In vitro cytotoxicity of NC@PDA-NH2, NC, or free imatinib after 48 h of co-incubation in TC-1 cells (D) or SiHa cells (E). (F,G) Apoptotic cell populations determined by flow cytometry with Annexin V-FITC and propidium iodide (PI) staining after co-incubation with NC@PDA-NH2, NC, or free imatinib in TC-1 cells (E) or SiHa cells (G). The lower-left (Q3), lower-right (Q4), upper-right (Q2), and upper-left (Q1) quadrants in each panel indicate the populations of normal, early, and late apoptotic, and apoptotic necrotic cells, respectively.
Figure 3. Cellular uptake and cytotoxicity in cervical cancer-related cell lines. (A) Representative CLSM images of TC-1 cells co-incubated with 6-coumarin (C6)-labeled NC@PDA-NH2, NC, or free probe C6 (green signal). The nucleus was stained with 2-(4-amidinophenyl)-6-indolecarbamindine dihydrochloride (DAPI; blue) and the lysosomes were stained with LysoTracker Red. (B) Flow cytometry analysis on the fluorescent intensity of cells after co-incubation for 2 h with C6-labeled NC@PDA-NH2, NC, or free probe in TC-1 cells. (C) Intracellular drug content after co-incubation for 72 h with NC@PDA-NH2, NC, or free imatinib in TC-1 cells (n = 5, mean ± SD, ** represents p < 0.01). (D,E) In vitro cytotoxicity of NC@PDA-NH2, NC, or free imatinib after 48 h of co-incubation in TC-1 cells (D) or SiHa cells (E). (F,G) Apoptotic cell populations determined by flow cytometry with Annexin V-FITC and propidium iodide (PI) staining after co-incubation with NC@PDA-NH2, NC, or free imatinib in TC-1 cells (E) or SiHa cells (G). The lower-left (Q3), lower-right (Q4), upper-right (Q2), and upper-left (Q1) quadrants in each panel indicate the populations of normal, early, and late apoptotic, and apoptotic necrotic cells, respectively.
Pharmaceutics 15 02188 g003
Pharmaceutics 15 02188 g006
Figure 6. In vivo evaluation in orthotopic TC-1 cervicovaginal model tumor-bearing mice after intravaginal administration of different formulations every other day. (A) Dose-dependent inhibition on the tumor size after three-week treatment (dose: 2, 4, and 8 mg/kg/2 d). (B) Penetration of fluorescent signal into the vaginal mucosa (4 h after administration). (C) Tumor weights after treatment for three weeks (dose: 4 mg/kg/2 d; n = 6). (D) Survival time (dose: 4 mg/kg/2 d; n = 10). (E) Change in anima body weight (dose: 4 mg/kg/2 d; n = 10). (F) Representative immunohistochemical microphotographs of tumor sections stained for apoptosis after three-week treatment (dose: 4 mg/kg/2 d). (G) Representative H&E microphotographs of tumors and vagina after three-week treatment (dose: 4 mg/kg/2 d). * indicates p < 0.05, ** indicates p < 0.01.
Figure 6. In vivo evaluation in orthotopic TC-1 cervicovaginal model tumor-bearing mice after intravaginal administration of different formulations every other day. (A) Dose-dependent inhibition on the tumor size after three-week treatment (dose: 2, 4, and 8 mg/kg/2 d). (B) Penetration of fluorescent signal into the vaginal mucosa (4 h after administration). (C) Tumor weights after treatment for three weeks (dose: 4 mg/kg/2 d; n = 6). (D) Survival time (dose: 4 mg/kg/2 d; n = 10). (E) Change in anima body weight (dose: 4 mg/kg/2 d; n = 10). (F) Representative immunohistochemical microphotographs of tumor sections stained for apoptosis after three-week treatment (dose: 4 mg/kg/2 d). (G) Representative H&E microphotographs of tumors and vagina after three-week treatment (dose: 4 mg/kg/2 d). * indicates p < 0.05, ** indicates p < 0.01.
Pharmaceutics 15 02188 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ci, L.-q.; Huang, Z.-g.; Lv, F.-m.; Wang, J.; Feng, L.-l.; Sun, F.; Cao, S.-j.; Liu, Z.-p.; Liu, Y.; Wei, G.; et al. Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15. Pharmaceutics 2023, 15, 2188. https://doi.org/10.3390/pharmaceutics15092188

AMA Style

Ci L-q, Huang Z-g, Lv F-m, Wang J, Feng L-l, Sun F, Cao S-j, Liu Z-p, Liu Y, Wei G, et al. Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15. Pharmaceutics. 2023; 15(9):2188. https://doi.org/10.3390/pharmaceutics15092188

Chicago/Turabian Style

Ci, Li-qian, Zhi-gang Huang, Feng-mei Lv, Jun Wang, Ling-lin Feng, Feng Sun, Shui-juan Cao, Zhe-peng Liu, Yu Liu, Gang Wei, and et al. 2023. "Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15" Pharmaceutics 15, no. 9: 2188. https://doi.org/10.3390/pharmaceutics15092188

APA Style

Ci, L. -q., Huang, Z. -g., Lv, F. -m., Wang, J., Feng, L. -l., Sun, F., Cao, S. -j., Liu, Z. -p., Liu, Y., Wei, G., & Lu, W. -y. (2023). Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15. Pharmaceutics, 15(9), 2188. https://doi.org/10.3390/pharmaceutics15092188

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop